Vivani Medical Announces Spin-Off of Cortigent Subsidiary

Vivani Medical ( (VANI) ) has issued an update.

On May 29, 2025, Vivani Medical announced the planned spin-off of its subsidiary, Cortigent, Inc., which will become an independent, publicly traded company on Nasdaq by the third quarter of 2025. Cortigent, a leader in precision neurostimulation technology, is developing the Orion Visual Cortical Prosthesis System and the Stroke Recovery System, both aimed at addressing critical unmet medical needs. The spin-off is expected to allow Vivani to focus on its NanoPortal drug implants while providing investors with clearer insights into the operations and strategies of both companies. This strategic move is anticipated to enhance value for Vivani and Cortigent stakeholders by creating two focused entities with distinct therapeutic priorities.

The most recent analyst rating on (VANI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.

Spark’s Take on VANI Stock

According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.

Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.

To see Spark’s full report on VANI stock, click here.

More about Vivani Medical

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal platform. These implants are designed for chronic weight management and type 2 diabetes, with the aim of improving patient adherence and tolerance to medication. Vivani’s lead programs include subdermal GLP-1 implants for chronic weight management and type 2 diabetes.

Average Trading Volume: 82,561

Technical Sentiment Signal: Sell

Current Market Cap: $67.54M

For an in-depth examination of VANI stock, go to TipRanks’ Stock Analysis page.